Position summary
Reporting into the Core Asset Team (CAT) Lead, the ideal candidate will lead the global commercial strategy and market development for the high-impact Immunology asset. The ideal candidate will own the go-to-market plan, geographic expansion, lifecycle strategy, and commercial business case plans for ex-US markets while staying in-sync and in step with the US Immunology functional leadership. The ideal candidate will seamlessly partner cross-functionally to accelerate early detection, diagnosis, an optimal treatment—delivering patient impact and business results.What you’ll doActively lead the Global Brand Plan strategy and long-range plan; align goals and priorities across markets.Build and execute go-to-market, Life Cycle Management (LCM) expansion, and market-shaping plans pre and post launch.Guide RDMA and clinical development with clear commercial input (positioning, TPP/TPC optimization, product claims).Develop commercial forecasts and the business case(s)-lead insights and market research, analytics, and scenario planning.Co-lead a high-performing Global Commercial Team (medical, marketing, operations, market research and regulatory) to help drive global brand planning, decision-making, resolve issues, and communicate to leadership both corporately and within regions / affiliates.Translate scientific and market insights into differentiated product strategy and value stories.Evaluate BD opportunities (e.g., in-licensing) and support feasibility studies.Represent commercial on product improvements (dosing, delivery systems, formulation).Partner closely with RDMA Medical Affairs, Programme / Project Management, Statistics, Regulatory, Operations, Pricing and Access, Legal, and regional commercial teams.